Zymeworks To Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

ZYME 10.10.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-10-31
Name of Upcoming Event:Conference Call
Full Press ReleaseSEC FilingsOur ZYME Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.08.2025 - Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
  • 12.12.2024 - Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Recent Filings

    Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

    October 10, 2024
    PDF Version

    VANCOUVER, British Columbia,Oct. 10, 2024(GLOBE NEWSWIRE) --Zymeworks Inc.(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close onOctober 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET).

    The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website athttps://ir.zymeworks.com/events-and-presentations

    AboutZymeworks Inc.

    Zymeworksis a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates.Zymeworksengineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary AzymetricTM technology.Zymeworkshas entered into separate agreements with BeiGene, Ltd. (BeiGene) andJazz Pharmaceuticals Ireland Limited(Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to theU.S. Food and Drug Administration(FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by theCenter for Drug Evaluation(CDE) of theNational Medical Products Administration(NMPA) inChina. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in theU.S.andChina.Zymeworksis rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting at sites worldwide. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information aboutZymeworks, visitwww.zymeworks.comand follow@ZymeworksIncon X.

    Contacts:

    Investor Inquiries:Shrinal InamdarDirector, Investor Relations(604) 678-1388ir@zymeworks.com

    Media Inquiries:Diana PapoveSenior Director, Corporate Communications(604) 678-1388media@zymeworks.com

    Primary Logo

    Source: Zymeworks Inc.

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com